KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EBIT (2018 - 2025)

Historic EBIT for Aurinia Pharmaceuticals (AUPH) over the last 9 years, with Q3 2025 value amounting to $29.7 million.

  • Aurinia Pharmaceuticals' EBIT rose 15319.2% to $29.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year increase of 31413.8%. This contributed to the annual value of -$4.7 million for FY2024, which is 9488.83% up from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its EBIT stood at $29.7 million for Q3 2025, which was up 15319.2% from $20.1 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' EBIT ranged from a high of $29.7 million in Q3 2025 and a low of -$50.5 million during Q1 2021
  • Moreover, its 5-year median value for EBIT was -$16.3 million (2023), whereas its average is -$16.7 million.
  • In the last 5 years, Aurinia Pharmaceuticals' EBIT crashed by 8678.12% in 2021 and then soared by 142736.29% in 2025.
  • Quarter analysis of 5 years shows Aurinia Pharmaceuticals' EBIT stood at -$32.7 million in 2021, then increased by 14.08% to -$28.1 million in 2022, then fell by 5.6% to -$29.7 million in 2023, then skyrocketed by 94.38% to -$1.7 million in 2024, then soared by 1882.2% to $29.7 million in 2025.
  • Its EBIT was $29.7 million in Q3 2025, compared to $20.1 million in Q2 2025 and $21.8 million in Q1 2025.